Reevaluating the prognostic value of RAS mutation status in patients with resected liver metastases from colorectal cancer: A systematic review and meta-analysis,Journal of Hepato-Biliary-Pancreatic Sciences

当前位置： X-MOL 学术 › J. Hepato Biliary Pancreat. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Reevaluating the prognostic value of RAS mutation status in patients with resected liver metastases from colorectal cancer: A systematic review and meta-analysis
Journal of Hepato-Biliary-Pancreatic Sciences ( IF 3.2 ) Pub Date : 2021-06-11 , DOI: 10.1002/jhbp.1007
Emmanouil Pikoulis ₁ , Dimitrios Papaconstantinou ₁ , Anastasia Pikouli ₁ , Jane Wang ₂ , Charalampos Theodoridis ₁ , Georgios Antonios Margonis ₃

Affiliation

Although the value of Rat Sarcoma Oncogene (RAS) mutation status in predicting long-term outcomes in patients with colorectal liver metastases (CRLM) is widely accepted, the magnitude of its impact has recently been challenged by three large cohort studies. The aim of this meta-analysis is to reevaluate the impact of RAS mutations on overall survival (OS) and disease-free survival (DFS) in patients who underwent curative-intent resection of CRLM.

中文翻译：

重新评估 RAS 突变状态对结直肠癌切除肝转移患者的预后价值：系统评价和荟萃分析

尽管大鼠肉瘤癌基因 (RAS) 突变状态在预测结直肠肝转移 (CRLM) 患者长期预后方面的价值已被广泛接受，但其影响的程度最近受到三项大型队列研究的挑战。本荟萃分析的目的是重新评估 RAS 突变对接受根治性切除 CRLM 的患者的总生存期 (OS) 和无病生存期 (DFS) 的影响。

更新日期：2021-06-11

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11